Clinical Trial News and Research

RSS

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

10 May 2011

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.

10 May 2011

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Sucampo Pharmaceuticals, Inc. and Abbott today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients.

10 May 2011

Teen alcohol consumption associated with computer use

Teenagers who drink alcohol spend more time on their computers for recreational use, including social networking and downloading and listening to music, compared with their peers who don't drink.

9 May 2011

Uganda: First vaccination for GMZ2 malaria vaccine trial

Today, the EDCTP-funded GMZ2 consortium starts volunteer enrolment for the phase IIb clinical trial of the candidate malaria vaccine GMZ2 in Uganda. This is the third trial site to initiate volunteer recruitment for this multi-country study. Vaccination is already underway at trial sites in Gabon (November 2010) and Burkina Faso (April 2011). The Uganda site is in the peri-urban area of Iganga/Mayuge, at the Iganga Hospital. Akin to most areas in Uganda, malaria is one of the major health problems in this district. A team from Makerere University (Kampala) is conducting the trial.

9 May 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

ImThera Medical concludes Phase I and II protocols for aura6000 European Pilot study in OSA

ImThera Medical, Inc. today announced that it has concluded its Phase I and Phase II protocols for the European Pilot study of the aura6000, a neurostimulation device for treating Obstructive Sleep Apnea (OSA). Clinical trial results from the study will be announced at the American Thoracic Society's International Conference on May 16, 2011 in Denver, CO.

9 May 2011

Advanced Cell Technology first quarter net loss decreases to $3.3 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations of $(4.8) million compared to a loss from operations of $(15.0) million in the 2010 first quarter.

9 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis, according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore.

7 May 2011

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

Data presented as a Late Breaking Clinical Trial at Heart Rhythm 2011, the Heart Rhythm Society's 32nd Annual Scientific Sessions, shows the clinical benefit of cardiac resynchronization therapy versus conventional right-ventricle pacing in improving heart failure in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation.

From Medtronic 7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

Roche seeks FDA clearance for fully automated Chlamydia and gonorrhoeae test

Roche announced today that it has filed for FDA clearance of its Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) tests.

7 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

SAS Health Care & Life Sciences Executive Conference to discuss clinical research best practices

Drug developers are challenged as never before to deliver innovative medicines through a business model that boosts the bottom line. Optimizing clinical trial design and portfolio management is paramount for managing outcomes and costs, and for rapidly advancing new drugs to the marketplace.

6 May 2011

Clinical Trial News and Research

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Teen alcohol consumption associated with computer use

Uganda: First vaccination for GMZ2 malaria vaccine trial

Novavax first quarter net loss decreases to $7.5 million

ImThera Medical concludes Phase I and II protocols for aura6000 European Pilot study in OSA

Advanced Cell Technology first quarter net loss decreases to $3.3 million

GTx reports net loss of $2.6 million for first quarter 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Roche seeks FDA clearance for fully automated Chlamydia and gonorrhoeae test

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

SAS Health Care & Life Sciences Executive Conference to discuss clinical research best practices

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News